Abstract: Disclosed herein is an isolated strain of Roseburia hominis HGM001, which is deposited at Deutsche Sammlung von Mikroorganismen and Zellkulturen GmbH under an accession number DSM 34119. A method for producing butyric acid using the isolated strain of Roseburia hominis HGM001, a fermented culture produced by the method, and a method for alleviating an inflammatory disorder using the fermented culture are also disclosed.

Abstract: A method of treating cancer includes administering a dose of a chemotherapy agent in combination with a dose of a composition consisting essentially of attenuated Salmonella typhimurium. The dose of the chemotherapy agent is lower than a maximum effective dose of the chemotherapy agent. The combination provides a synergistic reduction in tumor burden when compared to the reduction in tumor burden provided by administration of an equivalent dose of the chemotherapy agent without the composition consisting essentially of attenuated Salmonella typhimurium.

Abstract: The present invention is directed to methods of treatment of airway obstruction associated with fibrin-containing cast formation by administering a fibrinolytic agent.

Abstract: Disclosed herein are probiotic bacterial strains or species that produce short chain fatty acids (SCFA), such as butyrate, and compositions comprising the same. The bacterial strains or compositions prepared thereby are used in preparing food, supplements, compositions, and other consumables to provide health benefits, including therapeutic applications, for a variety of disorders, including metabolic, immune, intestinal, and inflammatory disorders. Thus, also disclosed herein are methods of treating a subject suffering from a disorder, such as a metabolic disorder, an immune disorder, an intestinal disorder, or an inflammatory disorder with a composition comprising the probiotic bacterial strains or species disclosed herein. Uses of a bacterial strain or species and a composition comprising them provided in a nutritional product or medicament to improve health or prevent or treat a variety of disorders in a subject are also disclosed.

Abstract: The present invention relates to microbial lysozyme, compositions comprising such and uses thereof.

Abstract: The present invention provides, in part, formulations comprising an alkaline phosphatase (AP)-based agent. Particularly, modified-release powder formulations comprising an AP-based agent are provided which release a substantial amount of the AP-based agent in the intestines. Therapeutic uses of the formulations are also provided.

Abstract: The present disclosure is directed to methods of treating a steatosis-associated disorder and methods of treating a cytoplasmic glycogen storage disorder, including glycogen storage disease I, glycogen storage disease III, glycogen storage disease IV, and/or conditions associated with a PRKAG2 mutation, by administering a therapeutic agent selected from a lysosomal enzyme, an autophagy-inducing agent, or a combination thereof. Steatosis-associated disorders discussed herein include GSD Ia, GSD Ib, GSD Ic, NAFLD, and NASH. Other embodiments are directed to methods of reversing steatosis, modulating autophagy, inducing autophagy, and reversing glycogen storage. Methods of treating a cytoplasmic glycogen storage disorder by administering a lysosomal enzyme and a second therapeutic agent are also described. Other embodiments are directed to methods of treating a cytoplasmic glycogen storage disorder by administering a therapeutic agent as an adjunctive therapy to lysosomal enzyme replacement therapy.

Abstract: Disclosed are pharmaceutical compositions comprising a combination of five or more phages and a pharmaceutically acceptable carrier, as well as methods of treating, reducing, or preventing a disease caused by Mycobacterium tuberculosis in a mammal, methods of treating an antibiotic resistant infection in a mammal, and methods of treating, reducing, or preventing activation of a latent disease caused by M. tuberculosis.

Abstract: An improved bacterial oil treatment composition or pool for handling a decommissioned oil cable, which may be laid in particular as part of a power grid in the ground. The invention further relates to a bacteria growth culture medium containing the bacterial oil treatment composition for refurbishing an oil cable and a corresponding use.

Abstract: The present invention provides methods for the cultivation of the Methylobacterium genus of bacteria. In particular the method provides methods for the efficient and inexpensive cultivation of these bacteria. Additionally, the invention provides methods for the utilization of these bacterial cultures to improve plant agriculture.

Abstract: Microbial starter cultures. More specifically, a method for preparing a microbial culture such as a lactic acid bacteria (LAB) starter culture wherein at least one microbial strain such as a lactic acid bacteria and at least one inactivated yeast strain is inoculated in a culture medium.

Abstract: Soil plant productivity is improved by manipulation of soil microflora. The soil microflora is manipulated by addition of a bacterium belonging to Rhizobium (Rhizobiales) to the soil.

Abstract: The invention relates to systems and methods for effective production and use of microorganisms and/or the fermentation broth in which they are produced. Advantageously, the system is cost-effective, scalable, quick, versatile, efficacious, and helpful in reducing resistance to chemical compounds and residue that concerns consumers.

Abstract: Systems and methods that include starch derived from grain as a carbon source for propagation of microorganisms.

Abstract: Methods, compositions, and kits are provided for rapidly analyzing microbial growth and/or number in a plurality of water-in-oil emulsion droplets.

Abstract: This invention provides, in part, various compositions and methods for protecting the gastrointestinal microbiome from antibiotic disruption.

Abstract: In one aspect, nutraceutical compositions, methods of preparation and methods of use comprise a nutraceutical composition comprising an antimicrobial hevamine A-related protein from Momordica balsamina alone or in combination with one or more nutraceutical ingredients. In another aspect, a method of preventing or treating a microbial infection in a plant comprises applying an effective amount of a composition containing the hevamine A-related protein to a whole plant, plant part, or media in which the plant is growing. In a further aspect, the present application provides a transgenic plant stably transformed with a polynucleotide encoding the hevamine A-related protein.

Abstract: An enhanced caffeinated beverage composition includes a caffeinated drink combined with an effective blend of methylliberine and theacrine providing increased mood, energy, alertness, focus, motivation, and/or decreased fatigue without adversely affecting heart rate or blood pressure.

Abstract: The process of making a biocomposite material utilize a bacterial species and a fungal species in an agricultural feedstock composed of a substrate of non-nutrient discrete particles and a nutrient material wherein the bacterial species imparts mechanical properties to the biocomposite material and the fungal species binds the biocomposite material. Both bacterium and fungus can be genetically engineered to produce desired properties within the microbial communities.

Abstract: A method for reducing hemolysis and microparticle formation during storage of pathogen reduced blood. Oxygen reduced blood compositions comprising SAGM and riboflavin having reduced hemolysis. Oxygen reduced blood compositions comprising SAGM and riboflavin having reduced microparticles. Oxygen and pathogen reduced blood compositions comprising CPAD and riboflavin having reduced hemolysis. Oxygen and pathogen reduced blood compositions comprising SAGM and riboflavin having reduced microparticles.